ANL 13.70 Decreased By ▼ -0.64 (-4.46%)
ASC 13.40 Decreased By ▼ -0.55 (-3.94%)
ASL 14.04 Decreased By ▼ -1.06 (-7.02%)
BOP 8.40 Decreased By ▼ -0.12 (-1.41%)
BYCO 6.33 Decreased By ▼ -0.21 (-3.21%)
FCCL 17.92 Decreased By ▼ -0.88 (-4.68%)
FFBL 25.00 Decreased By ▼ -1.85 (-6.89%)
FFL 10.60 Decreased By ▼ -0.40 (-3.64%)
FNEL 10.20 Decreased By ▼ -0.31 (-2.95%)
GGGL 15.45 Decreased By ▼ -0.80 (-4.92%)
GGL 29.95 Decreased By ▼ -1.55 (-4.92%)
HUMNL 6.02 Decreased By ▼ -0.22 (-3.53%)
JSCL 16.40 Decreased By ▼ -0.49 (-2.9%)
KAPCO 32.70 Decreased By ▼ -0.40 (-1.21%)
KEL 3.16 Decreased By ▼ -0.11 (-3.36%)
MDTL 2.35 Increased By ▲ 0.08 (3.52%)
MLCF 34.50 Decreased By ▼ -2.60 (-7.01%)
NETSOL 98.51 Decreased By ▼ -4.29 (-4.17%)
PACE 4.36 Decreased By ▼ -0.32 (-6.84%)
PAEL 21.50 Decreased By ▼ -1.65 (-7.13%)
PIBTL 7.70 Decreased By ▼ -0.16 (-2.04%)
POWER 6.60 Decreased By ▼ -0.45 (-6.38%)
PRL 12.95 Decreased By ▼ -0.71 (-5.2%)
PTC 8.75 Decreased By ▼ -0.15 (-1.69%)
SILK 1.28 Decreased By ▼ -0.03 (-2.29%)
SNGP 38.85 Decreased By ▼ -2.85 (-6.83%)
TELE 16.26 Decreased By ▼ -0.73 (-4.3%)
TRG 82.72 Decreased By ▼ -5.03 (-5.73%)
UNITY 23.60 Decreased By ▼ -1.75 (-6.9%)
WTL 2.13 Decreased By ▼ -0.07 (-3.18%)
BR100 4,534 Decreased By ▼ -136.87 (-2.93%)
BR30 17,939 Decreased By ▼ -895.02 (-4.75%)
KSE100 44,211 Decreased By ▼ -1157.66 (-2.55%)
KSE30 17,083 Decreased By ▼ -493.17 (-2.81%)

Coronavirus
LOW Source: covid.gov.pk
Pakistan Deaths
28,745
824hr
Pakistan Cases
1,285,631
37724hr
0.85% positivity
Sindh
476,017
Punjab
443,240
Balochistan
33,488
Islamabad
107,765
KPK
180,146

THE HAGUE: The EU's drug watchdog said Thursday it expected to decide in early October whether to approve boosters of the Pfizer/BioNTech Covid-19 vaccine for over 16s.

A decision on further jabs of both the Pfizer and Moderna vaccines for at-risk people and the elderly is due at the same time, the European Medicines Agency (EMA) said.

Protection against coronavirus is shown to decrease in the months following the first jabs, the Amsterdam-based regulator's head of vaccine strategy Marco Cavaleri told a news conference.

"The available data are showing that immunity against Covid-19 from initial vaccination wanes over time, and the protection from infection and symptomatic disease is decreasing in different parts of the world," Cavaleri said.

As a result, the EMA is now evaluating Pfizer's application for the use of a third booster dose at least six months after the second dose in people aged 16 or older.

EU hits goal of delivering vaccines for 70% of adults

"The outcome of this evaluation is expected in early October unless supplementary information is needed," Cavaleri said.

The EMA expert also said the "evidence was becoming clearer" on the need for boosters shortly after the first jabs for people with weakened immune systems who "respond poorly" to the initial vaccination.

Hospitalisation rates in the elderly were starting to rise as the initial jabs wore off, Cavaleri said.

The watchdog would "consider by early October if any specific recommendation can be included in product information" for the Moderna and Pfizer vaccines for such people, Cavaleri said.

Some EU countries were starting to give boosters to at-risk people ahead of a possible winter spike in Covid cases ahead of authorisation, Cavaleri said.

The EMA "acknowledged and understood" this decision, he added.

The watchdog meanwhile expects to make decisions on approving Covid vaccines for younger children in coming months.

Pfizer is due to submit data on trials for children aged 5-11 in early October, and Moderna in November, with decisions likely four weeks afterwards in each case, Cavaleri said.

The regulator has currently approved four vaccines for use in the 27-nation EU: Pfizer and Moderna, which use messenger RNA technology, and AstraZeneca and Johnson & Johnson, which use viral vector technology.

Only Pfizer and Moderna are so far approved for use in children aged 12 and up.

We love hearing your feedback, please help us improve by answering these few survey questions

Comments

Comments are closed.